Literature DB >> 21745566

Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging.

Jeffrey M Burns1, Robyn A Honea, Eric D Vidoni, Lewis J Hutfles, William M Brooks, Russell H Swerdlow.   

Abstract

We assessed the relationship of insulin resistance with cognitive decline and brain atrophy over two years in early Alzheimer's disease (AD, n=48) and nondemented controls (n=61). Intravenous glucose tolerance tests were conducted at baseline to determine insulin area-under-the-curve (AUC). A standard battery of cognitive tasks and MRI were conducted at baseline and 2-year follow-up. In nondemented controls, higher baseline insulin AUC was associated with 2-year decline in global cognitive performance (beta=-0.36, p=0.005). In early AD, however, higher insulin AUC was associated with less decline in global cognitive performance (beta=0.26, p=0.06), slower global brain atrophy (beta=0.40, p=0.01) and less regional atrophy in the bilateral hippocampi and cingulate cortices. While insulin resistance is associated with cognitive decline in nondemented aging, higher peripheral insulin may have AD-specific benefits or insulin signaling may be affected by systemic physiologic changes associated with AD. This article is part of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21745566      PMCID: PMC3264795          DOI: 10.1016/j.bbadis.2011.06.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  53 in total

1.  Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

Authors:  L Gasparini; G K Gouras; R Wang; R S Gross; M F Beal; P Greengard; H Xu
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53.

Authors:  A Yamaguchi; M Tamatani; H Matsuzaki; K Namikawa; H Kiyama; M P Vitek; N Mitsuda; M Tohyama
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

3.  Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.

Authors:  Stephen M Smith; Yongyue Zhang; Mark Jenkinson; Jacqueline Chen; P M Matthews; Antonio Federico; Nicola De Stefano
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

4.  Serum insulin-like growth factor I regulates brain amyloid-beta levels.

Authors:  E Carro; J L Trejo; T Gomez-Isla; D LeRoith; I Torres-Aleman
Journal:  Nat Med       Date:  2002-11-04       Impact factor: 53.440

5.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study.

Authors:  Rita Peila; Beatriz L Rodriguez; Lenore J Launer
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

6.  Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons.

Authors:  H Matsuzaki; M Tamatani; N Mitsuda; K Namikawa; H Kiyama; S Miyake; M Tohyama
Journal:  J Neurochem       Date:  1999-11       Impact factor: 5.372

7.  Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study.

Authors:  S Ahtiluoto; T Polvikoski; M Peltonen; A Solomon; J Tuomilehto; B Winblad; R Sulkava; M Kivipelto
Journal:  Neurology       Date:  2010-08-25       Impact factor: 9.910

8.  Mild cognitive impairment represents early-stage Alzheimer disease.

Authors:  J C Morris; M Storandt; J P Miller; D W McKeel; J L Price; E H Rubin; L Berg
Journal:  Arch Neurol       Date:  2001-03

9.  Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype.

Authors:  S Craft; S Asthana; G Schellenberg; L Baker; M Cherrier; A A Boyt; R N Martins; M Raskind; E Peskind; S Plymate
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

10.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

Authors:  Christopher J Phiel; Christina A Wilson; Virginia M-Y Lee; Peter S Klein
Journal:  Nature       Date:  2003-05-22       Impact factor: 49.962

View more
  37 in total

Review 1.  Metabolic Alterations Associated to Brain Dysfunction in Diabetes.

Authors:  João M N Duarte
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 2.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

Review 3.  Estrogen: a master regulator of bioenergetic systems in the brain and body.

Authors:  Jamaica R Rettberg; Jia Yao; Roberta Diaz Brinton
Journal:  Front Neuroendocrinol       Date:  2013-08-29       Impact factor: 8.606

4.  Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers.

Authors:  Erika J Starks; J Patrick O'Grady; Siobhan M Hoscheidt; Annie M Racine; Cynthia M Carlsson; Henrik Zetterberg; Kaj Blennow; Ozioma C Okonkwo; Luigi Puglielli; Sanjay Asthana; N Maritza Dowling; Carey E Gleason; Rozalyn M Anderson; Nancy J Davenport-Sis; LeAnn M DeRungs; Mark A Sager; Sterling C Johnson; Barbara B Bendlin
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Neurocognition in treatment-resistant hypertension: profile and associations with cardiovascular biomarkers.

Authors:  Patrick J Smith; James A Blumenthal; Alan L Hinderliter; Stephanie M Mabe; Jeanne E Schwartz; Forgive Avorgbedor; Andrew Sherwood
Journal:  J Hypertens       Date:  2019-05       Impact factor: 4.844

6.  Regional brain shrinkage over two years: individual differences and effects of pro-inflammatory genetic polymorphisms.

Authors:  N Persson; P Ghisletta; C L Dahle; A R Bender; Y Yang; P Yuan; A M Daugherty; N Raz
Journal:  Neuroimage       Date:  2014-09-28       Impact factor: 6.556

7.  Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin.

Authors:  Jill K Morris; Eric D Vidoni; Jonathan D Mahnken; Robert N Montgomery; David K Johnson; John P Thyfault; Jeffrey M Burns
Journal:  Neurobiol Aging       Date:  2015-12-01       Impact factor: 4.673

Review 8.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

9.  Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults.

Authors:  Amber S Watts; Natalia Loskutova; Jeffrey M Burns; David K Johnson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 10.  Is Alzheimer's disease a systemic disease?

Authors:  Jill K Morris; Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  Biochim Biophys Acta       Date:  2014-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.